The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: NCT06082050). This trial's primary objectives are to ...
In the updated NDRL, TYVYT® expands its coverage to the seventh new indication for the treatment of patients with epidermal growth factor receptor (EGF...
9MW2821 is a novel Nectin-4 targeting ADC developed independently by Mabwell, marking the first of its kind among the products developed in China with the ...
Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT) Merck to receive an exclusive commercial license ...
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -...
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Test...
A wave of respiratory illnesses, accompanied by alarming clusters of pneumonia cases, has inundated hospitals in northern China, sparking deep concerns abo...
With a steadfast dedication of 22 years to advancing the fundamental technologies of raw materials, reagent and instrument, Fapon strives to empower the gl...
Partnership agreement signed on 22 November to broaden distribution and promotion of cough and cold brands such as Shidagong, Gelite and Ruike in China&n...
The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...
"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...
U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales HUTCHMED (China) Limited (Nasdaq/AIM:HC...
© 2025 Biopharma Boardroom. All Rights Reserved.
